Financials (USD)
Sales 2024 * | 611M | Sales 2025 * | 705M | Capitalization | 2.35B |
---|---|---|---|---|---|
Net income 2024 * | 117M | Net income 2025 * | 183M | EV / Sales 2024 * | 3 x |
Net cash position 2024 * | 521M | Net cash position 2025 * | 621M | EV / Sales 2025 * | 2.46 x |
P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
14.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 68.25% |
Latest transcript on Corcept Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Atabak Mokari
DFI | Director of Finance/CFO | 47 | 21-02-28 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 46 | 12-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Belanoff
FOU | Founder | 66 | 98-05-12 |
Gregg Alton
BRD | Director/Board Member | 58 | 20-03-11 |
George Baker
BRD | Director/Board Member | 81 | 98-12-31 |
1st Jan change | Capi. | |
---|---|---|
+27.97% | 676B | |
+23.58% | 554B | |
-7.02% | 349B | |
+14.85% | 318B | |
+6.25% | 291B | |
+2.96% | 210B | |
-0.41% | 204B | |
-10.02% | 194B | |
-11.81% | 144B |